Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Incyte Corporation
Incyte Announces Final Results of Tender Offer
June 13, 2024
From
Incyte Corporation
Via
Business Wire
Tickers
INCY
Incyte Announces Preliminary Results of Tender Offer
June 11, 2024
From
Incyte Corporation
Via
Business Wire
Tickers
INCY
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
May 13, 2024
From
Incyte Corporation
Via
Business Wire
Tickers
INCY
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
March 10, 2024
From
Incyte Corporation
Via
Business Wire
Tickers
INCY
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 01, 2023
From
Incyte Corporation
Via
Business Wire
Tickers
INCY
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
March 18, 2023
From
Incyte Corporation
Via
Business Wire
Tickers
INCY
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
March 18, 2023
From
Incyte Corporation
Via
Business Wire
Tickers
INCY
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
March 14, 2023
From
Incyte Corporation
Via
Business Wire
Tickers
INCY
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
February 24, 2023
From
Incyte Corporation
Via
Business Wire
Tickers
INCY
Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo
March 14, 2022
From
Incyte Corporation
Via
Business Wire
Tickers
INCY
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
February 08, 2022
From
Incyte Corporation
Via
Business Wire
Tickers
INCY
Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
July 23, 2021
From
Incyte Corporation
Via
Business Wire
Tickers
INCY
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
June 11, 2021
From
Incyte Corporation
Via
Business Wire
Tickers
INCY
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.